SCV-07: Phase II started

SciClone began an open-label Phase II trial to evaluate 0.1 and 1.0 mg/kg of subcutaneous SCV-07 given as a monotherapy for 4 weeks then in combination with ribavirin for another 4 weeks in 40 non-cir...